Manipal Hospitals
| Índia | Turquia | Áustria | |
| Terapia por protões para cancro da próstata | de $35,000 | de $30,000 | de $80,000 |
| Terapia de radiação para o cancro colorretal | de $3,200 | de $7,000 | de $12,000 |
| Terapia de protões para cancro da mama | de $26,000 | de $30,000 | de $55,000 |
| Terapia de protão | de $25,000 | de $70,000 | de $80,000 |
| Terapia de Radiação para Sarcomas | de $4,500 | de $3,250 | de $18,000 |
A Bookimed não adiciona taxas extras aos preços de tratamento de Leiomiossarcoma. As tarifas vêm das listas oficiais de preços das clínicas. O pagamento é feito diretamente na clínica na chegada ao país.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais no tratamento de Leiomiossarcoma e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de tratamento de Leiomiossarcoma.
A Dra. Shruti Kate é especialista no tratamento de cancros avançados com imunoterapia e terapia metronómica, com investigação apresentada na Conferência Mundial sobre Cancro do Pulmão.
Realizou mais de 50.000 cirurgias de cancro ao longo de 19 anos – O Dr. Raj é especialista em oncologia cirúrgica mamária e torácica.
Realizou mais de 30.000 exames de PET e tratou 1.000 pacientes com cancro da tiroide – o Dr. Borde é especialista em medicina nuclear no HCG Manavata Cancer Centre.
Surgery is the primary treatment for Leiomyosarcoma in India. Surgeons perform radical resection to achieve clear margins. Specialized centers combine surgery with radiation or chemotherapy. Treatment follows National Cancer Grid standards. Multidisciplinary teams manage complex cases to ensure local control and prevent spread.
Bookimed Expert Insight: India offers a high density of oncology expertise across specialized hubs like Chennai and Gurgaon. Clinics like Global Hospital Chennai and Dr. Rela Institute often utilize linear accelerators with 1 mm accuracy for tumor irradiation. This precision is vital for Leiomyosarcoma near critical organs. Patients should look for NABH-accredited facilities to ensure these technology standards are met.
Patient Consensus: Patients note that surgery is the first step whenever the tumor is removable. Many emphasize the need to confirm that pathology and imaging resources are available on-site for faster results.
Major Indian oncology centers provide both genomic and hormone receptor testing for Leiomyosarcoma. Facilities use Next-Generation Sequencing to identify mutations in rare soft tissue sarcomas. Immunohistochemistry is standard for checking hormone receptor status. These diagnostics guide personalized treatment and target specific molecular alterations.
Bookimed Expert Insight: Indian hospitals like HCG Manavata use IBM Watson to help select cancer treatments. This combines local clinical data with global research to interpret complex genomic profiling. This technology bridges the gap between raw testing data and clear treatment steps. It is especially useful for rare conditions like Leiomyosarcoma where standard protocols often change.
Patient Consensus: Patients note that pathology quality remains the most critical factor. They recommend verifying the original diagnosis with a specialized sarcoma pathologist before starting expensive molecular testing.
India offers immunotherapy and clinical trials for leiomyosarcoma through specialized oncology centers. These treatments are often available at institutions like HCG Manavata Cancer Centre and Medanta Hospital. Participation in research trials is common for advanced cases that do not respond to standard surgery or radiation.
Bookimed Expert Insight: Patient volume is a major indicator of clinical trial access in India. HCG Manavata Cancer Centre serves over 100,000 patients globally. Its lead surgeon, Dr. Raj Nagarkar, has performed over 50,000 surgeries and led complex phase 1-3 trials. Choosing centers with high surgical volumes often provides more robust infrastructure for emerging therapies like immunotherapy.
Patient Consensus: Patients emphasize the need to ask directly about active recruitment for leiomyosarcoma rather than general sarcomas. They note that bringing full pathology reports is essential for biomarker-driven trial eligibility.
Patients should seek care at high-volume oncology centers in Bengaluru, Gurgaon, and Chennai for leiomyosarcoma. Specialized facilities like Manipal Hospitals and Medanta Hospital provide multidisciplinary tumor boards. These institutions utilize advanced imaging and precise surgical resection. Integrated care focuses on preventing recurrence through wide-margin oncology surgery.
Bookimed Expert Insight: A clear pattern emerges among India's top cancer centers: they centralize expertise from premier public institutions. For example, key specialists at HCG Manavata Cancer Centre, including Dr. Shruti Kate and Prof. Dr. Raj Nagarkar, completed their advanced training at Tata Memorial Hospital. Choosing a private center often grants faster access to this specific high-volume expertise alongside advanced technologies like the Da Vinci robotic system.
Patient Consensus: Patients note it is important to choose a facility where the surgical leads have specific sarcoma training rather than general surgery backgrounds. Many emphasize that having PET-CT and advanced imaging on-site speeds up the treatment planning significantly.
India maintains a robust network of dedicated sarcoma specialists focused on bone and soft-tissue tumors. These experts operate within multidisciplinary teams at major oncology hubs. Centers like HCG Manavata and Global Hospital utilize JCI-accredited facilities to provide specialized leiomyosarcoma care and advanced surgical interventions.
Bookimed Expert Insight: While general oncology is available nationwide, the highest concentration of sarcoma expertise remains in Bengaluru, Chennai, and Mumbai. For example, Global Hospital Chennai and Manipal Hospitals serve over 80,000 and 2,000,000 patients annually. This high volume allows surgeons to maintain specialized skills in rare tumor resections that smaller facilities may not encounter frequently.
Patient Consensus: Patients note it is essential to seek a second pathology review because sarcoma subtypes are often misclassified. Many emphasize that traveling to high-volume centers in major cities significantly improves the quality of the treatment plan.
Leiomyosarcoma treatment in India requires between 14 days and 4 months depending on the medical approach. Localized surgery usually necessitates 10 to 14 days for recovery. Complex systemic therapies like multi-cycle chemotherapy or daily radiation protocols extend the necessary stay to several months.
Bookimed Expert Insight: Indian oncology centers like HCG Manavata and Fortis Gurgaon utilize high-precision diagnostics that can shorten the pre-surgical phase. Dr. Raj Nagarkar has performed over 50,000 procedures, emphasizing that expert surgical speed often reduces initial hospital stays. However, advanced LMS cases may involve retroperitoneal surgery, which typically requires a more cautious 2-week inpatient observation period.
Patient Consensus: Patients emphasize the need for flexible return flights since post-operative wound checks or drain removals often change original timelines. It is widely recommended to bring specialized pathology slides from home to prevent diagnostic delays upon arrival.
Indian hospitals typically accept foreign pathology slides for review. Major institutions like Manipal Hospitals and Fortis Gurgaon require internal verification before starting leiomyosarcoma treatment. Local pathologists must re-examine tissue blocks to confirm tumor margins and grading. This step ensures diagnostic accuracy and protocol alignment.
Bookimed Expert Insight: Our data shows a high preference for major cancer centers like HCG Manavata for rare conditions. Dr. Raj Nagarkar there has performed over 50,000 surgeries. This massive volume means pathology departments at such centers are experts at identifying subtle leiomyosarcoma subtypes. Choosing a facility that handles over 75,000 patients yearly often lead to faster slide review cycles.
Patient Consensus: Patients note it's important to bring actual tissue blocks, not just paper reports. Many found that internal reviews confirmed the diagnosis but refined the treatment plan for better outcomes.